Skip to main content

Table 1 Patient and clinical characteristics among 196 ovarian tumors from the VUMC TROC

From: Expression of p52, a non-canonical NF-kappaB transcription factor, is associated with poor ovarian cancer prognosis

Characteristic N or median % * or std dev
Age at diagnosis, years 58.3 (13.9)
Progression-free survival, years 1.6 (3.8)
Overall survival, years 3.6 (6.1)
Race
 White 180 (91.8)
 Black 12 (6.1)
 Other 3 (1.5)
 Unknown 1 (0.51)
Stage
 I 50 (25.6)
 II 8 (4.1)
 III 116 (59.5)
 IV 21 (10.8)
 Unknown 1 (0.5)
Histologic subtype
 Serous 143 (72.9)
 Endometrioid 24 (12.2)
 Mucinous 15 (7.7)
 Clear cell 11 (5.6)
 Other a 3 (1.5)
Grade - among all types b
 Borderline 19 (9.7)
 Low-grade 33 (16.8)
 High-grade 144 (73.5)
Grade - among invasive serous
 Low-grade 13 (9.9)
 High-grade 118 (90.1)
Debulking status
 Debulked - optimal debulking 60 (30.6)
 Debulked - suboptimal debulking 53 (27.0)
 Not debulked or residual unknown 29 (14.8)
 Not applicable 54 (27.6)
Chemotherapy treatment
 Platinum and/or taxane agent(s) 152 (77.6)
 None or unknown 44 (22.4)
Response to platinum treatment c
 Platinum sensitive 105 (70.0)
 Platinum resistant or refractory 30 (20.0)
 Unknown 15 (10.0)
  1. * Percentages may not sum to 100 due to rounding error
  2. a Includes one case each: carcinosarcoma, primary squamous cell carcinoma, and a small cell carcinoma
  3. b High-grade includes high-grade serous, grade 3 endometrioid and mucinous, and all clear cell and carcinosarcomas. Low-grade includes low-grade serous, and grade 1–2 endometrioid and mucinous cancers
  4. c Among patients who had documentation of receiving platinum chemotherapy (N = 150)
\